6. The pipeline report evaluates Diabetic Nephropathy (Metabolic Disorders) therapeutics
based on mechanism of action (MoA), drug target, route of administration (RoA) and
molecule type.
7. The pipeline report encapsulates all the dormant and discontinued pipeline projects.
Buy a Copy of Report @ http://www.reportsnreports.com/purchase.aspx?name=928836.
List of Tables
1. Number of Products under Development for Diabetic Nephropathy, H1 2017
2. Products under Development by Companies, H1 2017
3. Products under Development by Universities/Institutes, H1 2017
4. Diabetic Nephropathy - Pipeline by AbbVie Inc, H1 2017
5. Diabetic Nephropathy - Pipeline by Allergan Plc, H1 2017
6. Diabetic Nephropathy - Pipeline by Antisense Therapeutics Ltd, H1 2017
7. Diabetic Nephropathy - Pipeline by Aptevo Therapeutics Inc, H1 2017
8. Diabetic Nephropathy - Pipeline by Variant Pharmaceuticals Inc, H1 2017
9. Diabetic Nephropathy - Pipeline by Vascular Pharmaceuticals Inc, H1 2017
10. Diabetic Nephropathy - Pipeline by Vicore Pharma AB, H1 2017
11. Diabetic Nephropathy - Pipeline by XORTX Pharma Corp, H1 2017
Inquire for Discount
http://www.reportsnreports.com/contacts/discount.aspx?name=928836 .
Companies Involved in Therapeutics Development
Abbvie Inc, Allergan Plc, Antisense Therapeutics Ltd , Aptevo Therapeutics Inc, Araim
Pharmaceuticals Inc, Arena Pharmaceuticals Inc, Astellas Pharma Inc, Astrazeneca Plc, Bayer
AG, BLR Bio LLC, Boehringer Ingelheim Gmbh, Cellmid Ltd, Chemocentryx Inc, CSL Ltd, Daiichi
Sankyo Company Ltd, Diamedica Therapeutics Inc, Dynamis Therapeutics Inc.
Diabetic Nephropathy Market - Drug Profiles
11-RVIVIT - Drug Profile ,A-717 - Drug Profile ,Antibodies To Inhibit Heparanase For Alopecia,
Colitis, Diabetic Nephropathy, Transplantation And Oncology - Drug Profile ,APD-371 - Drug
Profile ,APX-115 - Drug Profile ,ASP-8232 - Drug Profile,Atesidorsen Sodium - Drug Profile
,Atrasentan Hydrochloride - Drug Profile ,BI-703704 - Drug Profile ,BL-5923 - Drug Profile ,BLR-
200 - Drug Profile ,C-21 - Drug Profile ,Canagliflozin - Drug Profile ,CCX-140 - Drug Profile ,Cell
Therapy For Chronic Kidney Disease And Metabolic Disorders - Drug Profile.
List of Figures
1.
2.
3.
4.
Number of Products under Development for Diabetic Nephropathy, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Number of Products by Top 10 Targets, H1 2017